InSite Vision Dumps Canada's QLT for Sun Pharma

Sep 17, 2015

California-based InSite Vision has terminated its agreement with QLT Inc. in favor of entering a merger agreement with a subsidiary of Sun Pharmaceutical Industries.

InSite and Sun have entered into a merger agreement under which an indirect wholly owned subsidiary of Sun Pharma will acquire InSite in an all-cash transaction for $0.35 per share, or approximately $48 million.

In connection with InSite’s termination of the QLT merger agreement, InSite was required to pay a $2,667,000 termination fee to QLT. Sun Pharma has paid this fee to QLT on InSite’s behalf.

Vancouver-based QLT is a biotech company specializing in ocular products. The acquisition of InSite, a developer of specialty ophthalmology drugs, would have added two approved products to QLT’s portfolio: AzaSite conjunctivitis treatment and Besivance, an antibiotic for eye infections.

Read the InSite press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments